Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Diagnosing IBD by Evaluating Epigenetic Markers in Blood

By Gerald M. Slutzky, PhD
Posted on 07 Dec 2016
Epigenetic screening of blood samples has been proposed as a new approach to diagnosing patients with inflammatory bowel diseases (IBD).

Symptoms are similar in Crohn's disease, ulcerative colitis, and other inflammatory bowel conditions, which makes it difficult for doctors to diagnose which of the illnesses a patient has.

In an effort to develop better diagnostic tools for IBD, investigators at the University of Edinburgh (United Kingdom) used Illumina (San Diego, CA, USA) instruments and microarray technology to determine differentially methylated sites in whole blood and in immunomagnetically separated leucocytes (CD4+ and CD8+ lymphocytes and CD14+ monocytes) from 240 newly-diagnosed IBD cases and 190 controls.

The investigators reported that they had identified differentially methylated positions (DMPs) and regions (DMRs) in whole-blood DNA samples from 240 newly diagnosed IBD cases (121 Crohn's disease and 119 ulcerative colitis) and 191 controls. More...
Technical validation and detailed characterization of DMRs was performed in a small cohort of six cases (three Crohn's disease and three ulcerative colitis) and three controls using whole-genome bisulphite sequencing. Independent validation of methylation results was performed using bisulphite pyrosequencing in a further cohort of 240 patients with established IBD and 98 controls.

Senior author Dr. Jack Satsangi, professor of gastroenterology at the University of Edinburgh, said, "Our findings bring fresh insights to the underlying causes of inflammatory bowel diseases, which could eventually lead to new treatments. Characterizing epigenetic signatures in the DNA of patients could help us to devise better tests for diagnosing these diseases, so that patients can be given the best possible care."

The study was published in the November 25, 2016, online edition of the journal Nature Communications.

Related Links:
University of Edinburgh
Illumina

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
HPV Test
Allplex HPV28 Detection
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.